Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial

Abstract

Background:

Ketamine research in depression has mostly used intravenous, weight-based approaches, which are difficult to translate clinically. Intranasal (IN) ketamine is a promising alternative but no controlled data has been published on the feasibility, safety and potential efficacy of repeated IN ketamine treatments.

Methods:

This randomised, double-blind, placebo-controlled pilot study compared a 4-week course of eight treatments of 100 mg ketamine or 4.5 mg midazolam. Each treatment was given as 10 separate IN sprays, self-administered 5 min apart. The study was stopped early due to poor tolerability after five treatment-resistant depressed participants were included. Feasibility, safety (acute and cumulative), cognitive and efficacy outcomes were assessed. Plasma ketamine and norketamine concentrations were assayed after the first treatment.

Results:

Significant acute cardiovascular, psychotomimetic and neurological side effects occurred at doses < 100 mg ketamine. No participants were able to self-administer all 10 ketamine sprays due to incoordination; treatment time occasionally had to be extended (>45 min) due to acute side effects. No hepatic, cognitive or urinary changes were observed after the treatment course in either group. There was an approximately two-fold variation in ketamine and norketamine plasma concentrations between ketamine participants. At course end, one participant had remitted in each of the ketamine and midazolam groups.

Conclusions:

IN ketamine, with the drug formulation and delivery device used, was not a useful treatment approach in this study. Absorption was variable between individuals and acute tolerability was poor, requiring prolonged treatment administration time in some individuals. The drug formulation, the delivery device, the insufflation technique and individual patient factors play an important role in tolerability and efficacy when using IN ketamine for TRD.

Keywords

Ketamine treatment-resistant depression intranasal spray randomised controlled trial adverse effects efficacy

Get full access to this article

View all access options for this article.

References

Aan het Rot

Collins

Murrough

et al . (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67: 139–145.

Andrade

(2015) Intranasal drug delivery in neuropsychiatry: Focus on intranasal ketamine for refractory depression. J Clin Psychiatry 76: 628–631.

Berman

Cappiello

Anand

et al . (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351–354.

Bradfield

(1965) Reservations on the safety of oxytocin nasal spray in obstetrics. Aust N Z J Obstet Gynaecol 5: 138–143.

Bremner

Krystal

Putnam

et al . (1998) Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11: 125–136.

Daly

Singh

Fedgchin

et al . (2016) Intranasal esketamine in treatment resistant depression – a double-blind, randomized, efficacy and dose response study. In: 71st Society of Biological Psychiatry annual meeting, 12–14 May, Atlanta, Georgia, USA, 2016.

Diazgranados

Ibrahim

Brutsche

et al . (2010) A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67: 793–802.

Djupesland

(2013) Nasal drug delivery devices: Characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Res 3: 42–62.

Glue

Loo

Rodgers

et al . (2017) Comments on Cooper et al.’s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant. World J Biol Psychiatry 18: 489.

10.

Guastella

Hickie

McGuinness

et al . (2013) Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology 38: 612–625.

11.

Humphrey

Arbuckle

Moldwin

et al . (2012) The bladder pain/interstitial cystitis symptom score: development, validation, and identification of a cut score. Eur Urol 61: 271–279.

12.

Xiang

Fang

et al . (2016) Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med 46: 623–635.

13.

Kushwaha

SKS

Keshari

Rai

(2011) Advances in nasal trans-mucosal drug delivery. J Appl Pharm Sci 1: 21–28.

14.

Lai

Katalinic

Glue

et al . (2014) Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry 15: 579–584.

15.

Lapidus

Levitch

Perez

et al . (2014) A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 76: 970–976.

16.

Loo

Galvez

O’Keefe

et al . (2016) Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand 134: 48–56.

17.

Luckenbaugh

Niciu

Ionescu

et al . (2014) Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord 159: 56–61.

18.

McGirr

Berlim

Bond

et al . (2015) A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 45: 693–704.

19.

Montgomery

Asberg

(1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389.

20.

Murrough

Iosifescu

Chang

et al . (2013a) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170: 1134–1142.

21.

Murrough

Perez

Pillemer

et al . (2013b) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74: 250–256.

22.

Posner

Brown

Stanley

et al . (2011) The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168: 1266–1277.

23.

Pouget

Wattiez

Rivaud-Pechoux

et al . (2010) Rapid development of tolerance to sub-anaesthetic dose of ketamine: an oculomotor study in macaque monkeys. Psychopharmacology (Berl) 209: 313–318.

24.

Rasmussen

Lineberry

Galardy

et al . (2013) Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 27: 444–450.

25.

Rush

Fava

Wisniewski

et al . (2004) Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25: 119–142.

26.

Sackeim

(2001) The definition and meaning of treatment-resistant depression. J Clin Psychiatry 62(Suppl 16): 10–17.

27.

Segmiller

Ruther

Linhardt

et al . (2013) Repeated S-ketamine infusions in therapy resistant depression: a case series. J Clin Pharmacol 53: 996–998.

28.

Shafer

(2005) Meta-analysis of the brief psychiatric rating scale factor structure. Psychol Assess 17: 324–335.

29.

Shiroma

Johns

Kuskowski

et al . (2014) Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 155: 123–129.

30.

Sos

Kirova

Novak

et al . (2013) Relationship of ketamine’s antidepressant and psychomimetic effects in unipolar depression. Neuroendocrinology Letters 34: 287–293.

31.

Hackett

Carter

et al . (2016) Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol 19: pii: pyv124.

32.

Yanagihara

Ohtani

Kariya

et al . (2003) Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 24: 37–43.

33.

Young

Biggs

Ziegler

et al . (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133: 429–435.

34.

Zanos

Moaddel

Morris

et al . (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533: 481–486.

35.

Zarate

Jr Brutsche

Ibrahim

et al . (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71: 939–946.

36.

Zarate

Jr Singh

Carlson

et al . (2006) A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856–864.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.38 MB